Red blood cell in vitro quality and function is maintained after S‐303 pathogen inactivation treatment. Issue 7 (11th March 2014)

• Record Type: Journal Article
• Authors: Winter, Kelly M.; Johnson, Lacey; Kwok, Matthew; Vidovic, Diana; Hyland, Ryan A.; Mufti, Nina; Erickson, Anna; Marks, Denese C.
• Is Part Of: Transfusion. Volume 54:Issue 7(2014)
• Page Start: 1798
• Page End: 1807
• Publication Date: 2014-03-11
• Subjects: Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.12545
• Languages: English
• ISSNs: 0041-1132

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="trf12545-sec-0001" sec-type="section"> <title>Background</title> <p>Over the past decade there has been a growth in the development of pathogen reduction technologies to protect the blood supply from emerging pathogens. This development has proven to be difficult for red blood cells (RBCs). However the S‐303 system has been shown to effectively inactivate a broad spectrum of pathogens, while maintaining RBC quality.</p> </sec> <sec id="trf12545-sec-0002" sec-type="section"> <title>Study Design and Methods</title> <p>A paired three‐arm study was performed to compare the in vitro quality of S‐303–treated RBCs with RBCs stored at room temperature (RT) for the duration of the treatment (18‐20 hr) and control RBCs stored at 2 to 6°C. Products were sampled weekly over 42 days of storage (n = 10) and tested using an array of in vitro assays to measure quality, metabolism, and functional variables.</p> </sec> <sec id="trf12545-sec-0003" sec-type="section"> <title>Results</title> <p>During S‐303 treatment there was a slight loss of RBCs and hemoglobin (Hb < 5 g). Hemolysis, glucose consumption, and potassium release were similar in all groups during the 42 days of storage. S‐303–treated RBCs had a significantly lower lactate concentration and pH compared to the paired controls. The S‐303–treated RBCs had significantly higher adenosine triphosphate than the RT and control RBCs. There was a significant loss of 2, 3‐diphosphoglycerate in the S‐303–treated products, which was also observed in the RT RBCs. Flow cytometry analysis demonstrated similar RBC size, morphology, expression of CD47, and glycophorin A in all groups.</p> </sec> <sec id="trf12545-sec-0004" sec-type="section"> <title>Conclusion</title> <p>RBCs treated with S‐303 for pathogen reduction had similar in vitro properties to the paired controls and were within transfusion guidelines.</p> </sec> </abstract>